This paper is in the following e-collection/theme issue:

Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1484) JMIR Theme Issue: COVID-19 Special Issue (2394) Immunology, Allergy, Rheumatology (79) Prevention and Health Promotion (899) Reviews on Public Health Technology and Innovation (59)

Published on in Vol 7, No 4 (2021): April

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/25500, first published .
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Authors of this article:

Henry T Peng1 Author Orcid Image ;   Shawn G Rhind1 Author Orcid Image ;   Andrew Beckett2, 3 Author Orcid Image
Article Authors Cited by (16) Tweetations (9) Metrics

Journals

  1. Chitsike L, Duerksen-Hughes P. Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics. Virology Journal 2021;18(1) View
  2. Franchini M, Corsini F, Focosi D, Cruciani M. Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. Diagnostics 2021;11(9):1663 View
  3. Volk A, Covini-Souris C, Kuehnel D, De Mey C, Römisch J, Schmidt T. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. BioDrugs 2022;36(1):41 View
  4. Peng H, Rhind S, Moes K, Devine D, Jenkins C, Beckett A. Freeze‐dried plasma: From damage control resuscitation to coronavirus disease 2019 therapy. Transfusion 2022;62(7):1408 View
  5. Raclin T, Price A, Stave C, Lee E, Reddy B, Kim J, Chu L. Combining Machine Learning, Patient-Reported Outcomes, and Value-Based Health Care: Protocol for Scoping Reviews. JMIR Research Protocols 2022;11(7):e36395 View
  6. Muthuraman A, Ramesh M, Subramanian A, Dhamodharan J, Giap L. Overview of SARS-CoV-2 and Possible Targets for the Management of COVID-19 Infections. Coronaviruses 2022;3(5) View
  7. Xia W, Li M, Wang Y, Kazis L, Berlo K, Melikechi N, Chiklis G. Longitudinal analysis of antibody decay in convalescent COVID-19 patients. Scientific Reports 2021;11(1) View
  8. Kostandova N, Drabo E, Yenokyan K, Wesolowski A, Truelove S, Bloch E, Tobian A, Vassallo R, Bravo M, Casadevall A, Lessler J, Lau B. Comparison of allocation strategies of convalescent plasma to reduce excess infections and mortality from SARS‐CoV‐2 in a US‐like population. Transfusion 2023;63(1):92 View
  9. Husniah H, Ruhanda R, Supriatna A, Biswas M. SEIR Mathematical Model of Convalescent Plasma Transfusion to Reduce COVID-19 Disease Transmission. Mathematics 2021;9(22):2857 View
  10. Okonkwo C, Amusa L, Twinomurinzi H. COVID-Bot, an Intelligent System for COVID-19 Vaccination Screening: Design and Development. JMIR Formative Research 2022;6(10):e39157 View
  11. Khatri M, Mahalaxmi S. Elucidating the pathogenicity, diagnosis, treatment, and prevention of COVID-19: Part I. SRM Journal of Research in Dental Sciences 2022;13(3):127 View
  12. Korley F, Durkalski-Mauldin V, Yeatts S, Schulman K, Davenport R, Dumont L, El Kassar N, Foster L, Hah J, Jaiswal S, Kaplan A, Lowell E, McDyer J, Quinn J, Triulzi D, Van Huysen C, Stevenson V, Yadav K, Jones C, Kea B, Burnett A, Reynolds J, Greineder C, Haas N, Beiser D, Silbergleit R, Barsan W, Callaway C. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. New England Journal of Medicine 2021;385(21):1951 View
  13. Hussein A, Bakr E, Al-Jumaili M. Association between ABO blood groups and the risk of infection with SARS-CoV-2 in Iraq. Journal of International Medical Research 2022;50(11):030006052211331 View
  14. Tran A, Tassone D, Ding N, Nossent J. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). RMD Open 2023;9(1):e002871 View
  15. Wu J, Yang H, Yu D, Yang X. Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID. MedComm 2023;4(6) View
  16. Sideratou C, Papaneophytou C. Persistent Vascular Complications in Long COVID: The Role of ACE2 Deactivation, Microclots, and Uniform Fibrosis. Infectious Disease Reports 2024;16(4):561 View